GlassScriptPhysician profile
Michelle Soeun Chun
NPI 1487121679
$4,053.06
in general payments reported to CMS, 2019-2025
34 companies · $670 in 2025
The $670 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,297 · 2022: $1,052 · 2023: $492 · 2024: $542 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,314.69 | 2021-2025 | |
| Amarin Pharma, INC. | $555.03 | 2021-2023 | |
| Gilead Sciences, INC. | $306.99 | 2021-2025 | |
| Lilly USA, LLC | $257.90 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $209.47 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $187.89 | 2021-2024 | Prolia, Evenity |
| Eisai INC. | $121.95 | 2021-2022 | |
| Dexcom, INC. | $107.25 | 2023-2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $87.52 | 2021-2023 | |
| Astellas Pharma US INC | $81.71 | 2021-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $78.00 | 2022-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $64.66 | 2024-2025 | Gemtesa |
| Aimmune Therapeutics, INC. | $60.95 | 2025 | Zenpep |
| Exact Sciences Corporation | $60.82 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $59.73 | 2021-2025 | Airsupra, Farxiga |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $50.87 | 2022 | |
| Medtronic, INC. | $46.93 | 2025 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $42.03 | 2021 | |
| Vivus LLC | $41.64 | 2021-2023 | Qsymia |
| Phathom Pharmaceuticals, INC. | $35.72 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $33.14 | 2021 | |
| Redhill Biopharma INC. | $32.91 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $27.39 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.18 | 2023 | |
| Abbott Laboratories | $19.97 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $19.02 | 2024 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $18.57 | 2021 | |
| Vital Connect, INC | $17.84 | 2025 | Vitalpatch Rtm |
| Azurity Pharmaceuticals, INC. | $16.96 | 2024 | Horizant |
| Upsher-Smith Laboratories LLC | $16.90 | 2022 | |
| Shield Therapeutics INC | $15.31 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.78 | 2022 | |
| Ibsa Pharma INC. | $14.33 | 2022 | |
| Genentech USA, INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.